X-linked Hypophosphatemia: Burosumab (Crysvita) to the rescue
December 16, 2017 – As recent as of December 14, 2017, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the …
X-linked Hypophosphatemia: Burosumab (Crysvita) to the rescue Read more »